Silvia Ratto-KimMark S. De SouzaJeffrey R. CurrierNicos KarasavvasJohn SidneyMorgane RollandAnais Valencia-MicoltaSirinan MadnoteAlessandro SetteSorachai NitayaphanPunnee PitisuttuthumJaranit KaewkungwalSupachai Rerks-NgarmRobert O'ConnellNelson MichaelMerlin L. RobbMary MarovichJerome H. KimWalter Reed Army Institute of ResearchArmed Forces Research Institute of Medical Sciences, ThailandLa Jolla Institute for Allergy and ImmunologyMahidol UniversityThailand Ministry of Public HealthNational Institutes of Health, BethesdaNational Institute of Infectious DiseasesWater Reed Army Institute of Research2018-11-232018-11-232015-02-10PLoS ONE. Vol.10, No.2 (2015)193262032-s2.0-84922639329https://repository.li.mahidol.ac.th/handle/20.500.14594/35202We performed fine epitope mapping of the CD4+ responses in the ALVAC-HIV-AIDSVAX B/E prime-boost regimen in the Thai Phase III trial (RV144). Non-transformed Env-specific T cell lines established from RV144 vaccinees were used to determine the fine epitope mapping of the V2 and C1 responses and the HLA class II restriction. Data showed that there are two CD4+ epitopes contained within the V2 loop: one encompassing the α4β7 integrin binding site (AA179-181) and the other nested between two previously described genetic sieve signatures (AA169, AA181). There was no correlation between the frequencies of CD4+ fine epitope responses and binding antibody.Mahidol UniversityAgricultural and Biological SciencesBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1371/journal.pone.0115582